New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For ABBV;ABT;ALJ;ALDW;FB;WGP;WES;LRCX;WHF From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>
October 30, 2014
16:49 EDTALJAlon USA Energy reports Q3 EPS ex-items 59c, consensus 60c
Reports Q3 operational revenue $1.85B, may not compare to consensus $2.12B.
15:41 EDTABBVNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Exxon Mobil (XOM), consensus $1.73; Chevron (CVX), consensus $2.56; AbbVie (ABBV), consensus 77c; NextEra Energy (NEE), consensus $1.55; Dominion Resources (D), consensus 96c; Aon plc (AON), consensus $1.12; Weyerhaeuser (WY), consensus 30c; Clorox (CLX), consensus $1.03; Rockwell Collins (COL), consensus $1.27; Newell Rubbermaid (NWL), consensus 55c; Pinnacle West (PNW), consensus $2.15; Legg Mason (LM), consensus 0c; TECO Energy (TE), consensus 32c; Oshkosh (OSK), consensus 82c; Hilton Worldwide (HLT), consensus 17c; Genesee & Wyoming (GWR), consensus $1.17; Spirit AeroSystems (SPR), consensus 74c; Madison Square Garden (MSG), consensus 32c; Magellan Midstream (MMP), consensus 66c.
10:29 EDTFBFacebook post-earnings weakness continues, levels to watch
Shares are down 2.8% to $73.70, continuing the downtrend in place since earnings. At current price next support is at $72.63 and then at $71.33. Resistance is at $74.18.
09:21 EDTFBInstagram website, mobile app experienced outages this morning, BI says
Subscribe for More Information
09:14 EDTWESOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Visa (V), up 4%... MasterCard (MA), up 2.5%... Alcatel-Lucent (ALU), up 12.5%... TASER (TASR), up 4%... JDSU (JDSU), up 3.8%... Radian Group (RDN), up 9%... DreamWorks Animation (DWA), up 1.7%... Take-Two (TTWO), up 7.7%. ALSO HIGHER: Grand Canyon (LOPE), up 10.5%, upgraded at Piper Jaffray after the company formed a committee to explore conversion to a nonprofit entity... Walter Energy (WLT), up 6.8% after lowering FY14 capital expenditures view, reporting lower than expected losses... Novavax (NVAX), up 7% after getting fast track designation for H7N9 VLP. DOWN AFTER EARNINGS: Glu Mobile (GLUU), down 16.6%... Alliance Fiber Optic (AFOP), down 18.4%... Pacira (PCRX), down 6.4%. ALSO LOWER: Sturm, Ruger (RGR), down 10% following Q3 results, cutting Q3 dividend. Peer gunmaker Smith & Wesson (SWHC) also down 3.7% after Ruger's report... Western Gas Partners (WES), down 4.4% after its 7.5M common units spot secondary priced at $70.85... ACCO Brands (ACCO), down 1.1%, downgraded at KeyBanc following the company's Q3 results... Fiat Chrysler (FCAU), down 1.1% after reported to be recalling over 300K Ram trucks due to fire concern... Inogen (INGN), down 2.3% after 2.1M share secondary offering of common stock priced at $21.50.
08:53 EDTWESWestern Gas Partners 7.5M share Spot Secondary priced at $70.85
UBS, Morgan Stanley, Wells Fargo, Barclays, BofA/Merrill, Citigroup, Deutsche Bank, RBC Capital, Credit Suisse and Goldman acted as joint book running managers for the offering.
06:31 EDTFBFacebook files to sell 162.7M shares for WhatsApp stockholders
October 29, 2014
17:05 EDTFBOn The Fly: Closing Wrap
Subscribe for More Information
17:02 EDTALDWAlon USA Partners reports Q3 EPS $1.23, consensus $1.26
Subscribe for More Information
16:22 EDTWESWestern Gas Partners files to sell 7.5M common units
Subscribe for More Information
16:11 EDTFBFacebook files automatic mixed securities shelf
16:02 EDTFBOptions Update; October 29, 2014
Subscribe for More Information
12:58 EDTFBOn The Fly: Midday Wrap
Subscribe for More Information
12:20 EDTFBStocks with call strike movement; FB EA
Subscribe for More Information
11:09 EDTFBFacebook sinks after unveiling 2015 spending plans
Shares of Facebook (FB) are retreating after the company announced stronger than expected results but said its expenses would jump 50%-70% in 2015 compared to this year. A number of analysts remained upbeat on the company's outlook following its results and guidance. WHAT'S NEW: Facebook's third quarter earnings per share came in at 43c, above the consensus estimate of 40c. The company's revenue came in slightly above expectations. The social networking giant said that its monthly active users had risen 14% in Q3 versus the same period a year earlier to 1.35B. But the company added that its expenses would surge 50%-70% in fiscal 2015, compared with fiscal 2014. Facebook reported that it plans to invest in various new technologies, including artificial intelligence and virtual reality. ANALYST REACTION: In a note to investors, Cantor Fitzgerald analyst Youssef Squali wrote that the stock and the company's margins would likely be pressured in the near-term by its spending plans. But Facebook's outlook is still strong and its valuation is compelling, the analyst stated. Moreover, Facebook's margins should remain healthy, and its results were "excellent," he wrote. Squali cut his price target on the name to $80 from $82, but kept a Buy rating on the shares. Meanwhile, Goldman Sachs analyst Heather Bellini wrote that Facebook's spending next year is likely to come in below its guidance, as in the past, while the company's ad platform continues to have strong momentum. Facebook's ability to attract users across multiple devices and platforms is unparalleled and should enable the company to attract more ad dollars, the analyst wrote. She believes that the weakness in the stock today has created a buying opportunity. PRICE ACTION: In late morning trading, Facebook fell 6% to $76.
10:17 EDTABBVGilead retreats after Hepatitis C drug sales miss expectations
Shares of drug maker Gilead (GILD) are falling after the company last night announced lower than expected third quarter profits and reported sales of its Hepatitis C treatment, Sovaldi, that came in below expectations. WHAT'S NEW: Gilead reported Q3 earnings per share of $1.84, versus analysts' consensus estimate of $1.92. The company's revenue came in slightly above expectations. Gilead said its Sovaldi drug had generated $2.8B of sales last quarter. On average, analysts had expected sales of the drug to come in at $2.93B. Sales of Sovaldi dropped 20% in Q3 versus Q2. However, the company said on its earnings conference call that the launch of its new Hepatitis C treatment, Harvoni, was off to a strong start. ANALYST REACTION: In a note to investors earlier today, Bernstein analyst Geoffrey Porges wrote that Gilead's Q3 revenue and EPS were reduced by one-time events. Its EPS would have easily beaten expectations if the company did not have to pay one-time taxes related to the Affordable Care Act, Porges stated. The lower than expected Sovaldi sales were caused by a variety of factors, including anticipation of the Harvoni launch, the analyst believes. The challenges facing Sovaldi should not affect Harvoni's performance in Q4 and 2015, added Porges, who remains very upbeat on the company's overall Hepatitis C franchise for the near to medium term. He kept a $130 price target and Outperform rating on the shares. Analysts at UBS also remained positive on Gilead, writing that the company had a good quarter with its HIV franchise that resulted in a top-line beat despite the lower than expected Sovaldi sales. The firm said it remains bullish on the Harvoni launch and sees potential upside to estimates. UBS reiterated its Buy rating and $125 price target on Gilead shares. OTHERS TO WATCH: Other pharmaceutical companies offering and developing Hepatitis C treatments include Johnson & Johnson (JNJ) and Abbvie (ABBV). PRICE ACTION: In early trading, Gilead fell 2% to $111.25.
10:00 EDTABTOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: AMC Networks (AMCX) upgraded to Buy from Hold at ISI Group... Abbott (ABT) upgraded to Buy from Hold at Deutsche Bank... Ahold (AHONY) upgraded to Overweight from Neutral at JPMorgan... Alere (ALR) upgraded to Buy from Hold at Craig-Hallum... Ambev (ABEV) upgraded to Buy from Neutral at Goldman... Bayer (BAYRY) upgraded to Outperform from Market Perform at Bernstein... C.H. Robinson (CHRW) upgraded to Buy from Neutral at BofA/Merrill... Cliffs Natural (CLF) upgraded to Outperform from Neutral at Macquarie... HCC Insurance (HCC) upgraded at Raymond James... Hannon Armstrong (HASI) upgraded to Buy from Neutral at BofA/Merrill... Jamba (JMBA) upgraded to Outperform from Neutral at Wedbush... Midway Gold (MDW) upgraded to Speculative Buy from Hold at Canaccord... PG&E (PCG) upgraded to Buy from Hold at Deutsche Bank... RWE AG (RWEOY) upgraded to Neutral from Underweight at JPMorgan... Starwood (HOT) upgraded to Buy from Hold at Craig-Hallum... Total System (TSS) upgraded to Overweight from Equal Weight at Stephens.
09:42 EDTFBActive equity options trading
Subscribe for More Information
09:31 EDTABTAbbott acquires Topera
Subscribe for More Information
09:23 EDTFBFacebook should be bought on weakness, says RBC Capital
Subscribe for More Information
09:19 EDTFBOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Goodyear Tire (GT), up 10%... Electronic Arts (EA), up 3.7%... ZELTIQ (ZLTQ), up 9%... Eaton (ETN), up 2.3%... Anadarko (APC), up 2%... U.S. Steel (X), up 7.7%... IAC (IACI), up 3.6%. ALSO HIGHER: Fiat Chrysler (FCAU), up 12% after reporting quarterly results, announcing plan to spin off Ferrari... Cara Therapeutics (CARA), up 17.8% after HAL trial of IV formulation of CR845 met primary endpoint... Jamba (JMBA), up 4% after upgraded at Wedbush. DOWN AFTER EARNINGS: Facebook (FB), down 5.7%... Gilead (GILD), down 3.2%... Ralph Lauren (RL), down 2.3%... SodaStream (SODA), down 3%... Garmin (GRMN), down 5%... Applied Micro Circuits (AMCC), down 9.9%... STMicroelectronics (STM), down 10%... Ballard Power (BLDP), down 8.7%... Hershey (HSY), down 3.3%... Deutsche Bank (DB), down 2.3%... McKesson (MCK), down 2%. ALSO LOWER: Sanofi (SNY), down 5.7% after downgraded at various firms including Barclays and BofA/Merrill after the company's board removed Christopher Viehbacher as CEO... InvenSense (INVN), down 22%, downgraded at Pacific Crest, Northland and Piper Jaffray following the company's Q2 earnings results... CareTrust REIT (CTRE), down 3.6% after acquiring Cross Healthcare Seniors housing portfolio... Orbital (ORB), down 16% after Orb-3 launch mishap... American Realty (ARCP), down 22% after announcing resignations of CFO, CAO.
07:56 EDTFBFacebook shares should be bought on weakness, says Oppenheimer
Subscribe for More Information
07:55 EDTFBFacebook price target raised to $88 from $84 at Canaccord
Subscribe for More Information
07:38 EDTFBFacebook weakness an excellent buying opportunity, says Goldman
Subscribe for More Information
07:36 EDTFBFacebook reports WhatsApp net loss ($232M) in 1H
Subscribe for More Information
07:29 EDTFBFacebook price target lowered to $85 from $90 at JPMorgan
Subscribe for More Information
07:22 EDTABTAbbott upgraded to Buy from Hold at Deutsche Bank
Subscribe for More Information
06:55 EDTABTAbbott upgraded to Buy from Hold at Deutsche Bank
Subscribe for More Information
06:49 EDTFBFacebook to be well-positioned over long-term, says Cantor
After Facebook unexpectedly said that it would make aggressive investments next year, Cantor thinks the investments position the company to improve ihe engagement and monetization of its major websites over the long-term. The firm says the decision will pressure the stock and margins over the short-term, but it expects the company's margins to remain healthy and finds the stock's valuation compelling. It keeps a Buy rating.
06:31 EDTFBFacebook 10% sell-off 'seems appropriate,' says Deutsche Bank
Deutsche Bank says the 10% pullback in shares of Facebook following the company's Q3 results "seems appropriate" given reduced earnings expectations for all high multiple internet companies in the quarter and the upcoming 180M shares available for sale from the WhatsApp deal. Deutsche recommends adding to positions on weakness over the next several days as it continues to view Facebook as one of the best names in the space. It has a Buy rating on the stock with a $90 price target.
06:23 EDTFBFacebook thesis intact despite expense guidance, says Piper Jaffray
Piper Jaffray attributes the post-earnings sell-off in shares of Facebook to the company's unexpected guidance for Q4 revenue and 2015 expenses. Piper still sees multiple catalysts for Facebook including video, Audience Network, WhatsApp, Atlas, and Instagram. It keeps an Overweight rating on the stock with an $82 price target saying its thesis remains intact.
October 28, 2014
18:42 EDTWES, FBOn The Fly: After Hours Movers
Subscribe for More Information
18:02 EDTFBSocial media stocks lower after Facebook reports Q3 results
Subscribe for More Information
18:01 EDTFBFacebook says 'pretty far from being fully deployed' on ad strategy
Says video, news, and celebrity content are priorities. Sees more apps for sharing going forward. Says using FB to cross-promote Instagram. Says relationship with China is "very long-term."
17:39 EDTFBTwitter down over 1% to $43.20 in after hours after Facebook's Q3 results
17:34 EDTFBFacebook down nearly 8% following Q4, FY14, FY15 guidance
Subscribe for More Information
17:31 EDTFBFacebook sees Q4 tax rate 45%-50%
Says Q4 will be more difficult to compare.
17:29 EDTFBFacebook sees FY14 non-GAAP expenses up 30%-35% YoY
Subscribe for More Information
17:26 EDTFBFacebook sees Q4 revenue growth 40%-47% YoY, consensus $3.74B
Guidance from company's Q3 earnings conference call.
17:09 EDTWESWestern Gas Partners up 1.27% after reporting Q3 results, Nuevo acquisition
17:09 EDTWESWestern Gas Partners sees FY14 adjusted EBITDA $625M-$650M
Subscribe for More Information
17:08 EDTWESWestern Gas Partners reports Q3 EPS 60c, consensus 59c
Subscribe for More Information
17:05 EDTWESWestern Gas Partners to acquire Nuevo Midstream for $1.5B
Subscribe for More Information
17:04 EDTWESWestern Gas Partners to acquire Nuevo Midstream for $1.5B
Subscribe for More Information
16:05 EDTFBFacebook shares down 42c to $80.35 following Q3 results
Subscribe for More Information
16:05 EDTFBFacebook says Q3 Mobile advertising revenue 66% of ad revenue
Subscribe for More Information
16:03 EDTFBFacebook reports Q3 monthly active users up 14% to 1.35B
Subscribe for More Information
16:02 EDTFBFacebook reports Q3 EPS 43c, consensus 40c
Reports Q3 revenue $3.2B, consensus $3.12B.
16:00 EDTFBOptions Update; October 28, 2014
Subscribe for More Information
13:51 EDTFBEarnings Preview: Analysts positive on Facebook ahead of Q3 earnings
Facebook (FB) is expected to report third quarter earnings after the market close on Tuesday, October 28 with a conference call scheduled for 5:00 pm ET. Facebook is a social networking service with over 1B active users. EXPECTATIONS: Analysts are looking for earnings per share of 40c on revenue of $3.12B. The consensus range is 34c-47c for EPS, and $2.94B-$3.23B for revenue, according to First Call. LAST QUARTER: Facebook reported second quarter EPS of 42c against estimates of 34c, on revenue of $2.9B against estimates of $2.81B. The company reported daily active users of 829M on average for June, with mobile daily active users up 31% to 654M in March. Facebook said mobile ad revenue represented 62% of ad revenue and the company now has 1.5M active advertisers. Facebook said its Q2 price per ad was up 123% and it will focus on quality in roll-out of video ads. At the Q2 earnings conference call, Facebook said its push into commerce and payments is supplemental to advertising. NEWS: Facebook closed on its previously announced acquisition of WhatsApp for $22B, up $3B from its $19B price point due to the increased value in Facebook's stock over the past few months. CEO Mark Zuckerberg said he expects WhatsApp to reach 3B users, although the company does not have any imminent targets to gross any monetary funds from the platform. In the past quarter, Facebook also acquired security start-up PrivateCore and was in talks with major studios for content for Oculus Rift. The company shut down its Gifts business, but launched Atlas ad measuring platform and cross-device reporting for ads. It also announced a new research framework with stricter guidelines with a review panel, a six-week training program, and a research website. STREET RESEARCH: Ahead of Q3 earnings, Deutsche Bank recommended adding to Facebook positions, saying its proprietary checks on the company have been "solid all quarter." Oppenheimer said Facebook will likely beat Q3 expectations based on strong monetization trends. Cowen said Facebook is the premier social advertising platform, believing its numbers will continue to grow, especially on mobile devices. Citigroup said Q3 estimates have potential upside, thinking Facebook is seeing continued positive business momentum. Baird believes Facebook is well positioned to take market share in the display market, which is core to the firm's long-term positive view of the company. Evercore raised Facebook's price target based on the relaunch of the Atlas ad server platform that allows advertisers to better measure ad effectiveness across mobile and desktop in addition to providing new Display buying tools. PRICE ACTION: Facebook shares have gained over 13%, since the first day of trading following the company's Q2 report. In Tuesday afternoon trading ahead of its Q3 report, Facebook shares are up fractionally.
13:49 EDTFBFacebook October weekly 80 straddle priced for 7.2% move into Q3
Subscribe for More Information
12:55 EDTFBFacebook technical notes ahead of results
The shares have been strong outperformers in the last three months, trading up over 7%. Shares are close to the life high at $81.16 with an expectation that the company will deliver a strong report. Without overhead resistance, a report that exceeds already high expectations could push the stock into the $85 to $90 area depending on the degree of surprise. If there is a disappointment the first key level on a test would be at $70.32, a recent low of the trading range for the last three months. Additional support below would be at $67.56. News that fails to push the shares above the old high or below $70 would leave it range-bound in a neutral trend.
12:18 EDTFBTwitter slumps, downgraded after user growth slows
Subscribe for More Information
09:37 EDTFBActive equity options trading
Subscribe for More Information
07:50 EDTABTAbbott management to meet with Deutsche Bank
Subscribe for More Information
07:22 EDTFBIRI Worldwide to hold a conference
Subscribe for More Information
07:19 EDTFBFacebook October weekly volatility increases into Q3 and outlook
Subscribe for More Information
October 27, 2014
16:00 EDTFBOptions Update; October 27, 2014
iPath S&P 500 VIX Short-Term Futures down 52c to 32.66. Option volume leaders: AAPL TSLA TWTR AMZN FB NFLX GILD CLF PBR according to Track Data.
11:46 EDTFBStocks with call strike movement; NBR FB
Subscribe for More Information
10:00 EDTFBOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:37 EDTFBActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL PBR TWTR AMZN M NQ GILD C FB NFLX
09:14 EDTFBFacebook initiated with a Buy at Monness Crespi
Target $95.
07:50 EDTFBFacebook the premier social advertising platform, says Cowen
Cowen previewed Q3 earnings for Facebook and said they see it as the premier social advertising platform. The firm said Facebook's numbers continue to grow, especially on mobile devices, and they expect further monetization levers there and in other ad formats. Cowen said Facebook is one of their top picks in their universe and reiterates its Outperform rating and $90 price target on the shares.
07:29 EDTABBVWorldwide Business Research to hold a conference
ProcureCon Pharma 2014 is being held in Philadelphia on October 27-29.
07:21 EDTFBFacebook October weekly volatility elevated into Q3 and revenue outlook
Facebook October weekly volatility elevated into Q3 and revenue outlook Facebook October weekly 31 call option implied volatility is at 75, November is at 44, December is at 37, March is at 34; compared to its 26-week average of 38 according to Track Data, suggesting large near term price movement into the expected release of Q3 results on October 28. :theflyonthewall.com
October 26, 2014
16:55 EDTABBVShire CEO 'dumbfounded' by AbbVie's decision, Bloomberg says
Subscribe for More Information
October 24, 2014
16:02 EDTFBOptions Update; October 24, 2014
Subscribe for More Information
11:19 EDTFBFacebook October weekly volatility elevated into Q3 and revenue outlook
Subscribe for More Information
October 23, 2014
16:00 EDTFBOptions Update; October 23, 2014
iPath S&P 500 VIX Short-Term Futures down 2.04 to 33.48. Option volume leaders: AAPL TSLA TWTR F AMZN FB NFLX PBR P according to Track Data.
13:27 EDTFBFacebook launches Rooms app
Facebook earlier today announced that it would launch an app that will enable users to create chat rooms based on different topics. Reference Link
11:38 EDTFBStocks with call strike movement; FB VALE
Facebook (FB) March 90 call option implied volatility decreased 3% to 35, Vale (VALE) March 12 call option implied volatility decreased 3% to 33 according to IVolatility.
10:39 EDTABBVAbbVie advances after upbeat notes from JPMorgan, Goldman
Subscribe for More Information
10:01 EDTABBVOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:27 EDTLRCXLam Research remains a top pick for 2015 at Goldman
Subscribe for More Information
08:54 EDTABBVAbbVie reinstated with a Buy at Goldman
Subscribe for More Information
06:31 EDTABBVAbbVie resumed with an Overweight from Neutral at JPMorgan
Subscribe for More Information
06:22 EDTABTMylan, Abbott enter into amendment, still see deal closing in 1Q15
Subscribe for More Information
October 22, 2014
18:34 EDTLRCXOn The Fly: After Hours Movers
UP AFTER EARNINGS: Select Comfort (SCSS), up 13.1% after reporting third quarter results and increasing share repurchase authorization to $250M... Infinera (INFN), up 9.8%... Tractor Supply (TSCO), up 11.8%... Acacia Research (ACTG), up 7.7%... Marketo (MKTO), up 4.5%... O'Reilly Automotive (ORLY), up 3.9%... Fortinet (FTNT), up 1.5%... Mellanox (MLNX), up 2.9%... ServiceNow (NOW), up just under 1%. ALSO HIGHER: CarMax (KMX), up 1% after announcing a $2B increase to its share repurchase program. DOWN AFTER EARNINGS: Air Methods (AIRM), down 19.8% following preliminary third quarter results... Yelp (YELP), down 13.6%... Core Laboratories (CLB), down 7.9%... Varian Medical (VAR), down 4.9% after reporting fourth quarter results... Open Text (OTEX), down 3.9%... Citrix (CTXS), down 5.7%... Cheesecake Factory (CAKE), down 4.5%... Allied World (AWH), down 4.7%... Lam Research (LRCX), down 3.3%... Skechers (SKX), down just under 1% after reporting third quarter results above analyst estimates... AT&T (T), down 1.5%. ALSO LOWER: DIRECTV (DTV), down just under 1% following AT&T third quarter results... Alcobra (ADHD), down 16% following results of MDX study... WidePoint (WYY), down 8.1% after filing an automatic common stock shelf... New Mountain Finance (NMFC), down 4.4% after filing to sell 5M shares of common stock.
16:52 EDTLRCXLam Research down 3.3% after reporting Q3 results
Subscribe for More Information
16:16 EDTLRCXLam Research sees Q2 EPS $1.12 plus or minus 7c, consensus $1.16
Subscribe for More Information
16:15 EDTLRCXLam Research reports Q1 EPS 96c, consensus 93c
Reports Q1 revenue $1.15B, consensus $1.15B.
16:00 EDTFBOptions Update; October 23, 2014
Subscribe for More Information
15:37 EDTABBVNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Comcast (CMCSA), consensus 71c; Union Pacific (UNP), consensus $1.52; 3M (MMM), consensus $1.96; AbbVie (ABBV), consensus 77c; Celgene (CELG), consensus 95c; Eli Lilly (LLY), consensus 67c; Occidental Petroleum (OXY), consensus $1.57; Caterpillar (CAT), consensus $1.36; Alexion Pharmaceuticals (ALXN), consensus $1.16; Precision Castparts (PCP), consensus $3.32; Raytheon (RTN), consensus $1.60; American Electric Power (AEP), consensus $1.02; Southwest Airlines (LUV), consensus 53c; Lorillard (LO), consensus 90c; T. Rowe Price (TROW), consensus $1.15; Mead Johnson (MJN), consensus 91c; Zimmer Holdings (ZMH), consensus $1.30; Nucor (NUE), consensus 73c; Nielsen (NLSN), consensus 65c; Prologis (PLD), consensus 46c; Sigma-Aldrich (SIAL), consensus $1.06; Under Armour (UA), consensus 40c; EQT (EQT), consensus 56c; Dr Pepper Snapple (DPS), consensus 88c; Cameron International (CAM), consensus $1.10; Coca-Cola Enterprises (CCE), consensus 89c; Quest Diagnostics (DGX), consensus $1.08; CMS Energy (CMS), consensus 41c; Airgas (ARG), consensus $1.29; PulteGroup (PHM), consensus 36c; Diamond Offshore (DO), consensus 79c; Bemis (BMS), consensus 67c.
15:30 EDTLRCXNotable companies reporting after market close
Subscribe for More Information
13:42 EDTFBFacebook October weekly volatility elevated into Q3 and revenue outlook
Subscribe for More Information
09:38 EDTFBActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL PBR AMZN C TWTR YHOO BAC GILD FB THRX DOW CAR
09:24 EDTABTAbbott says on track for another year of double digit adjusted EPS growth
Subscribe for More Information
09:21 EDTABTOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Dow Chemical (DOW), up 3.7%... iRobot (IRBT), up 12%... Six Flags (SIX), up 13%... GlaxoSmithKline (GSK), up 2%... Broadcom (BRCM), up 7%... Boston Scientific (BSX), up 4.3%... Abbott (ABT), up 1.8%... Yahoo! (YHOO), up 6%. ALSO HIGHER: Blue Earth (BBLU), up 26.4% after CEO says statements in Seeking Alpha blog are "false and misleading."... GW Pharmaceuticals (GWPH), up 5.4% after Epidiolex receives orphan designation from EMA. DOWN AFTER EARNINGS: 3D Systems (DDD), down 15%... Biogen (BIIB), down 7%... Lumber Liquidators (LL), down 13.4%... Norfolk Southern (NSC), down 3%... Angie's List (ANGI), down 8.8%. ALSO LOWER: Nanosphere (NSPH), down 33% after filing secondary, reporting preliminary Q3 revenue... Himax Technologies (HIMX), down 16% after announcing that Google (GOOG) will not exercise an additional investment option in the company... Cree (CREE), down 10.5%, downgraded at DA Davidson and Canaccord following the company's Q1 earnings results... Ocwen Financial (OCN), down 7% after downgraded to Hold at Evercore, downgraded to Neutral at BofA Merrill Lynch... VMware (VMW), down 7.8%, downgraded at Nomura and Raymond James following the company's Q3 results.
09:19 EDTABBVAbbVie coverage resumed with an Overweight at Morgan Stanley
Subscribe for More Information
09:16 EDTABTAbbott sees Q4 reported sales growth in high single digits
Subscribe for More Information
09:14 EDTABTAbbott sees FY14 operational sales growth in the mid single digits
Sees foreign exchange to have negative impact of approx. 2% on FY reported sales, somewhat more negative than previous expectations. Sees FY14 reported sales growth in low to mid single digits. Sees FY gross margin ratio about 55% of sales. Comments made on the Q3 earnings conference call.
08:04 EDTABTAbbott raises FY14 adjusted EPS view to $2.25-$2.27 from $2.19-$2.29
Subscribe for More Information
07:37 EDTABTAbbott sees Q4 EPS excl items 68c-70c, consensus 70c
Subscribe for More Information
07:36 EDTABTAbbott reports Q3 Nutrition revenue $1.79B, Q3 Diagnostics revenue $1.19B
Subscribe for More Information
07:34 EDTABTAbbott reports Q3 EPS 62c, consensus 59c
Subscribe for More Information
October 21, 2014
16:00 EDTFBOptions Update; October 21, 2014
Subscribe for More Information
15:35 EDTABTNotable companies reporting before tomorrow's open
Subscribe for More Information
10:00 EDTABBVOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: AbbVie (ABBV) downgraded to Neutral from Buy at Guggenheim... BHP Billiton (BHP) downgraded to Hold from Buy at Jefferies... Bank of Marin (BMRC) downgraded to Market Perform from Outperform at Keefe Bruyette... Cobalt (CIE) downgraded to Speculative Buy from Buy at Global Hunter... Consolidated Edison (ED) downgraded to Underweight at Morgan Stanley... Deutsche Post (DPSGY) downgraded to Hold from Buy at Deutsche Bank... HCP (HCP) downgraded to Hold from Buy at Jefferies... IBM (IBM) downgraded to Hold from Buy at Evercore... Inland Real Estate (IRC) downgraded to Underperform from Neutral at BofA/Merrill... PerkinElmer (PKI) downgraded to Neutral from Buy at Janney Capital... Philips (PHG) downgraded to Neutral at UBS... QEP Midstream Partners (QEPM) downgraded to Market Perform at Wells Fargo... Rent-A-Center (RCII) downgraded to Market Perform from Outperform at Raymond James... Rhino Resources (RNO) downgraded to Underperform from Market Perform at Raymond James... Universal Forest (UFPI) downgraded to Neutral from Buy at Sterne Agee.
09:52 EDTABBVCovidien rises after Medtronic maintains merger date language
Shares of Covidien (COV) are rising in early trading after Medtronic (MDT), in its latest regulatory filing answering questions for shareholders regarding its proposed takeover of the Irish drugmaker, left its language regarding the expected closing date unchanged. WHAT'S NEW: In its most recent filing, Medtronic again stated, "As of the date of this joint proxy statement/prospectus, the transaction is expected to be completed late in the fourth calendar quarter of 2014 or early 2015. However, no assurance can be provided as to when or if the transaction will be completed. The required vote of Medtronic and Covidien shareholders to adopt the required shareholder proposals at their respective special meetings, as well as the necessary regulatory consents and approvals, must first be obtained and other conditions specified in the conditions appendix must be satisfied or, to the extent applicable, waived." ANALYST REACTION: Research firm BTIG says Medtronic's amended regulatory filing on the Covidien transaction increases the firm's confidence of the deal closing by early 2015. The firm adds it would be "stunned" to see Medtronic walk away from the merger after the company again showed commitment to the acquisition. WHAT'S NOTABLE: AbbVie (ABBV) last night confirmed that the company and Shire (SHPG), another Irish domiciled drugmaker, agreed to terminate their proposed merger. AbbVie said its decision was based upon its assessment of the September 22 notice issued by the U.S. Department of Treasury, which re-interpreted longstanding tax principles in a "uniquely selective manner designed specifically to destroy the financial benefits of these types of transactions." AbbVie continued that the Treasury notice "introduced an unacceptable level of risk and uncertainty given the magnitude of the proposed changes" and the stated intention of the department to continue to revise tax principles to further impact such "tax inversion" transactions. AbbVie noted that it has agreed to pay Shire a break fee of approximately $1.64B due to the deal falling through. PRICE ACTION: In early trading, shares of Covidien trading in New York rose 4% to $88.86, Medtronic advanced 1% to $64.57, Shires gained 0.7% to $185.82 and AbbVie added 1.4% to $55.16.
09:48 EDTABBVShire could target BioMarin, TheStreet's Feuerstein says
Subscribe for More Information
07:44 EDTABTAbbott volatility elevated into Q3 and outlook
Subscribe for More Information
06:34 EDTABBVAbbVie downgraded to Neutral from Buy at Guggenheim
Subscribe for More Information
06:09 EDTFBTwitter initiated with a Neutral at Citigroup
Subscribe for More Information
06:04 EDTFBFacebook sues laywers who represented Ceglia, Re/code reports
Subscribe for More Information
October 20, 2014
18:51 EDTABBVOn The Fly: After Hours Movers
Subscribe for More Information
18:49 EDTABBVEnanta will not exercise co-development option for ABT-493
Enanta Pharmaceuticals (ENTA) announced that it has decided not to exercise its co-development option for ABT-493, Enanta’s next-generation protease inhibitor for hepatitis C virus, or HCV, being developed in Enanta’s collaboration with AbbVie (ABBV). Per the original collaboration agreement signed in December 2006, Enanta will be eligible for certain regulatory approval milestones as well as royalties on net sales allocable to ABT-493 from worldwide sales of any ABT-493-containing regimens. Enanta also announced that it has reached agreement with AbbVie regarding the net sales allocations for royalty calculations for ABT-450-containing regimens, as well as any regimens containing ABT-493. ABT-450 is the first clinical-stage protease inhibitor candidate developed within the Enanta-AbbVie collaboration, and ABT-493 is the second.
17:34 EDTABBVAbbVie announces new $5B stock repurchase program, raises dividend nearly 17%
Subscribe for More Information
17:33 EDTABBVAbbVie announces new $5B stock repurchase program, raises dividend
17:26 EDTABBVShire down 1% following termination of merger with AbbVie
Subscribe for More Information
17:17 EDTABBVAbbVie to pay Shire $1.64B break fee
Subscribe for More Information
17:16 EDTABBVAbbVie, Shire announce termination of proposed merger
Subscribe for More Information
17:14 EDTABBVAbbVie, Shire announce termination of proposed merger
12:03 EDTFBKing Digital launches Candy Crush Soda Saga worldwide on Facebook
Earlier today, King Digital Entertainment (KING) announced that Candy Crush Soda Saga, the sister title to hit game Candy Crush Saga, has launched worldwide on Facebook (FB). Candy Crush Soda Saga is the next iteration in the Candy Crush franchise, set in the world of the Candy Kingdom. Fans of the original hit can now switch and match their way through new dimensions of gameplay with exciting new graphics and features including game modes, candy combinations, gameplay mechanics and more. Candy Crush Soda Saga is set to launch on mobile in the coming weeks.
11:42 EDTFBStocks with call strike movement; FB DAL
Subscribe for More Information
07:47 EDTABBVPfizer less likely to renew Astra pursuit after Shire deal breakdown, FT says
Subscribe for More Information
07:11 EDTABBVAmerican Society for Reproductive Medicine to hold annual meeting
2014 Annual Meeting of ASRM is being held in Honolulu on October 18-22.
06:56 EDTABBVShire reopens acquistion talks with NPS Pharmaceuticals, Cubist, Telegraph says
Subscribe for More Information
October 17, 2014
16:55 EDTABBVStocks end volatile week lower amid oil price plunge
Subscribe for More Information
16:01 EDTFBOptions Update; October 17, 2014
iPath S&P 500 VIX Short-Term Futures down 1.75 to 38.58 Option volume leaders: AAPL TSLA TWTR AMZN FB NFLX GILD CLF PBR according to Track Data.
10:00 EDTABBVOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:47 EDTABBVAbbVie initiated with a Buy at ISI Group
Subscribe for More Information
07:07 EDTABBVShire may be buyer instead of target if AbbVie deal breaks, WSJ says
Assuming AbbVie's (ABBV) deal to buy Shire (SHPG) gets cancelled, which appears likely at this point, many analysts and investors believe Shire will become a buyer and Leerink Partners estimates the company could have $10B to use for a takeover deal, reported The Wall Street Journal. AbbVie will also be likely to look for other deals and could be forced to pay up for them, as its top seller, Humira, moves closer to losing patent exclusivity, the Journal said, citing analysts. Reference Link
05:55 EDTABBVStocks with implied volatility movement; ABBV CSX
Subscribe for More Information
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use